Most Recent
A delegate of IP Australia has tossed opposition by veterinary pharmaceutical company Norbrook Laboratories to a patent by rival animal health specialist Bayer New Zealand for a bovine antiseptic treatment.
The company that operates the Newmarch House nursing home in Sydney is facing a possible class action after a coronavirus outbreak at the facility resulted in the deaths of 19 residents.
Drug manufacturer Janssen wants to expand its high stakes case against Juno Pharmaceuticals over its HIV drug Prezista, alleging Juno's plans to launch a generic version of the drug threaten another one of its patents.
Ariosa Diagnostics is fighting to revoke a patent for noninvasive prenatal test owned by Sequenom, arguing it merely describes how to extract "incorporeal" genetic information that is naturally found within the DNA of an unborn foetus.
Drug maker Janssen has fired off a lawsuit against Juno Pharmaceuticals for allegedly threatening to infringe a patent for its HIV drug Prezista with a generic version of the drug, one year after fending off generic competition from a different drug maker.
In a defeat to the Australian Securities and Investments Commission, a judge has found a key witness in the trial against former Quintis director Frank Wilson must give evidence in person, delaying the hearing indefinitely until coronavirus-related travel restrictions are lifted.
Medical technology company Respiri has settled a lawsuit brought by its former CEO alleging he was terminated for seeking to expand into the Indian market against the wishes of the ASX-listed company's board.
An employee from not-for-profit aged care health provider Ozcare who claims the company discriminated against her through its mandatory flu vaccine policies has had her case thrown out of the Fair Work Commission.
Animal health company Abbey Laboratories has successfully challenged an application by rival Bayer Australia for a patent covering a treatment for biting lice.
A penalty hearing in the ACCC's case against health booking company HealthEngine over misleading online reviews has been adjourned after a judge criticised the parties' joint submissions as "deficient" for failing to explain how a proposed $2.9 million penalty had been arrived at.